Sam Fazeli

And of course, when you look at the supplementary details there,

There was a major focus, as there should have been, on excluding patients with a risk of haemoptysis or history of haemoptysis.

And yet, there were some bleeding events on the trial.

So I still am sitting here a little bit worried that this ends up just being a PD-1 plus VEGF.

I don't know.

I don't know.

Actually, do you want to make a comment on that?

Or would you rather not?

I mean, you've definitely thrown the dice.

seriously on rivagostomig and you could say volarostomig too.

You know, I don't know.

I think we talked about this last time.

I counted something like 8,000 patients in total in the various rivagostomig trials.

I am hopeful.

I believe in your translational data.

That was beautiful to see at WCLC.

And of course I missed this time last year's CITSE presentation, but fingers crossed because I think it would be finally changing people's attitudes to more than

lag 3 and ctl a4 in single agent um or combo so

Just to touch on bladder cancer, non-muscle invasive bladder cancer.

Potomac trial delivered good EFS results, 0.68 in BCG-naive high-risk non-muscle invasive bladder cancer, which of course is a key thing there is to preserve the bladder, is what everybody tries to do with a variety of mechanisms.